DOP2017000016A - Nueva sal de disoproxilo de tenofovir - Google Patents

Nueva sal de disoproxilo de tenofovir

Info

Publication number
DOP2017000016A
DOP2017000016A DO2017000016A DO2017000016A DOP2017000016A DO P2017000016 A DOP2017000016 A DO P2017000016A DO 2017000016 A DO2017000016 A DO 2017000016A DO 2017000016 A DO2017000016 A DO 2017000016A DO P2017000016 A DOP2017000016 A DO P2017000016A
Authority
DO
Dominican Republic
Prior art keywords
salt
tenofovir disoproxyl
new
new tenofovir
disoproxyl
Prior art date
Application number
DO2017000016A
Other languages
English (en)
Inventor
Do-Kyu Pyun
Won Kyoung Lee
Su-Ha Park
Original Assignee
Jw Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jw Pharmaceutical Corp filed Critical Jw Pharmaceutical Corp
Publication of DOP2017000016A publication Critical patent/DOP2017000016A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/05—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing at least two sulfo groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE EXPONE UNA SAL NOVEDOSA DE DISOPROXILO DE TENOFOVIR EDISLATO TENIENDO LA ESTRUCTURA DE LA FÓRMULA QUÍMICA 1.
DO2017000016A 2014-07-18 2017-01-18 Nueva sal de disoproxilo de tenofovir DOP2017000016A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20140091262 2014-07-18

Publications (1)

Publication Number Publication Date
DOP2017000016A true DOP2017000016A (es) 2017-03-31

Family

ID=55078736

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2017000016A DOP2017000016A (es) 2014-07-18 2017-01-18 Nueva sal de disoproxilo de tenofovir

Country Status (14)

Country Link
US (1) US9879038B2 (es)
EP (1) EP3170829B1 (es)
JP (1) JP6421873B2 (es)
KR (1) KR101658870B1 (es)
CN (1) CN106795187B (es)
AU (1) AU2015290400B2 (es)
BR (1) BR112017000908B1 (es)
CA (1) CA2954491C (es)
DO (1) DOP2017000016A (es)
ES (1) ES2698516T3 (es)
MY (1) MY174957A (es)
PH (1) PH12017500076B1 (es)
RU (1) RU2660438C1 (es)
WO (1) WO2016010305A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230277587A1 (en) * 2022-03-03 2023-09-07 Dermacisen, S.A. Food supplement for oral administration

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005082364A1 (en) 2004-01-30 2005-09-09 Pfizer Inc. Compositions comprising hiv protease inhibitor and cytochrome p450 enzyme activity inhibitor
WO2006007448A2 (en) * 2004-06-17 2006-01-19 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions and related methods of use
ATE474560T1 (de) * 2005-12-14 2010-08-15 Cipla Ltd Pharmazeutische kombination aus nucleotid und nucleosid-reverse-transkriptase-hemmern (wie tenofovir und lamivudin) in verschiedenen teilen der dosiereinheit
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
JP2010527996A (ja) * 2007-05-22 2010-08-19 ウルティモルフィクス・テクノロジーズ・ベー・フェー テノホビルジソプロキシル−ヘミフマル酸共結晶
CN101918418A (zh) * 2007-12-12 2010-12-15 阿尔迪默菲克斯技术有限责任公司 替诺福韦地索普西的固体形式
NZ588796A (en) * 2008-04-25 2012-07-27 Cipla Ltd Crystalline form of tenofovir disoproxil and a process for its preparation
CN101574356A (zh) * 2008-05-07 2009-11-11 黑龙江加州国际投资咨询有限公司 泰诺福韦酯药用盐及其制剂
WO2010026603A2 (en) 2008-09-05 2010-03-11 Matrix Laboratories Limited Novel amine salts of tenofovir, process for producing the same and use thereof in production of tenofovir dioproxil
KR20110081382A (ko) * 2010-01-08 2011-07-14 경동제약 주식회사 결정성 아데포비어 디피복실 술폰산염 무수물, 그 제조방법 및 이를 포함하는 약제학적 조성물
WO2011100528A2 (en) * 2010-02-12 2011-08-18 Emory University Compositions and uses of lectins
ES2729824T3 (es) 2011-04-08 2019-11-06 Laurus Labs Ltd Formas sólidas de compuestos antirretrovirales, procedimiento para la preparación y composición farmacéutica de los mismos
CN103626803B (zh) * 2012-08-23 2017-12-15 四川海思科制药有限公司 替诺福韦二吡呋酯的固体及其制备方法和用途
KR101439255B1 (ko) 2012-08-30 2014-09-11 주식회사 종근당 테노포비어 디소프록실의 신규염 및 그의 제조방법
KR20150025993A (ko) 2013-08-30 2015-03-11 동아에스티 주식회사 테노포비어 디소프록실 산부가염 및 이의 제조방법

Also Published As

Publication number Publication date
RU2660438C1 (ru) 2018-07-06
CA2954491A1 (en) 2016-01-21
CA2954491C (en) 2018-12-04
AU2015290400A1 (en) 2017-02-02
KR20160026985A (ko) 2016-03-09
EP3170829B1 (en) 2018-09-19
EP3170829A1 (en) 2017-05-24
BR112017000908B1 (pt) 2022-09-13
PH12017500076A1 (en) 2017-05-22
WO2016010305A1 (ko) 2016-01-21
EP3170829A4 (en) 2017-07-05
JP6421873B2 (ja) 2018-11-14
CN106795187B (zh) 2019-08-13
CN106795187A (zh) 2017-05-31
PH12017500076B1 (en) 2020-02-19
AU2015290400B2 (en) 2017-12-07
MY174957A (en) 2020-05-28
KR101658870B1 (ko) 2016-09-22
US9879038B2 (en) 2018-01-30
ES2698516T3 (es) 2019-02-05
US20170152276A1 (en) 2017-06-01
JP2017526646A (ja) 2017-09-14
BR112017000908A2 (pt) 2017-11-21

Similar Documents

Publication Publication Date Title
UY36315A (es) COMPUESTOS NOVEDOSOS ANTAGONISTAS DE INTEGRINA avß6.
DK3728252T3 (da) 4-azaindolforbindelser
ECSP17029371A (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
GEAP202114450A (en) Anti-tigit antibodies
GEAP201814347A (en) Substituted dihydroisoquinoline compounds
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
EA201692219A1 (ru) Способы получения противовирусных соединений
UY36480A (es) Uso de compuestos de picolinamida como fungicidas
TR201905829T4 (tr) Buzdolabı.
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
TWD170698S (zh) 電動牙刷
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
MX2021012440A (es) Farmacos precursores de oxabicicloheptanos.
CL2015002358A1 (es) Compuestos bicíclicos.
CO2017005732A2 (es) Compuestos de dihidropirimidin-2-ona y sus usos médicos
IL241245A0 (en) Bicyclo [2.2.1] acid gpr120 modulators
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
BR112016027455A2 (pt) moduladores ppar
EP3171860C0 (en) SOLID ORAL FORMULATION OF FENRETINIDE
TWD177889S (zh) 牙刷
TWD173012S (zh) 手錶錶殼
DOP2017000016A (es) Nueva sal de disoproxilo de tenofovir
EA201690593A1 (ru) Новые соединения мочевины
TWD169899S (zh) 牙刷